Posted by Michael Wonder on 24 Aug 2021
Clovis Oncology announces availability of and reimbursement for Rubraca (rucaparib) tablets for women with relapsed ovarian cancer in Switzerland
24 August 2021 - Rubraca is commercially available in Germany, United Kingdom, Italy, Spain, France, Netherlands, United States of America and now in Switzerland.
Clovis Oncology today announced that Rubraca (rucaparib) is now available and reimbursed in Switzerland.
The Swiss authority responsible for the authorisation and supervision of therapeutic products (Swissmedic) gave a positive recommendation for Rubraca as maintenance treatment for recurrent platinum sensitive ovarian cancer.
